

Study: ENGOT-en23 / MK-2870

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active **
BS	Brescia	Spedali Civili	Germana Tognon	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna *	
RM	Roma	Ospedale Umberto I	Federica Tomao	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	

* **MaNGO Principal Investigator**

** **MaNGO sites list: to be confirmed by Sponsor**